ProCE Banner Activity

Protocol 011 at Wk 144: Islatravir + Doravirine in Treatment-Naive Persons With HIV

Slideset Download
Conference Coverage
In the phase IIb trial, continued high rates of efficacy were seen in the combined ISL plus DOR arm at 144 Weeks; no participants in this arm met criteria for resistance testing.

Released: November 03, 2021

Expiration: November 02, 2022

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.

ViiV Healthcare